Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22453868 | 0.93 | GLP1R (0.47) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL22566707 | 0.91 | GLP1R (0.52) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL18715649 | 0.91 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL22404807 | 0.91 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2FNTA | |
| SCHEMBL20375472 | 0.89 | GLP1R (0.46) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL21287416 | 0.88 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL20800966 | 0.88 | GLP1R (0.52) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL23714552 | 0.86 | GLP1R (0.51) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL20375678 | 0.86 | GLP1R (0.53) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL23714526 | 0.85 | GLP1R (0.50) | GLP1RLPAR3LPAR1TLR2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-12-30 | — | — | US | disclosed |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-10995335-B2 | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10780108-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-07-02 | — | — | US | disclosed |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Arrowhead Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | Arrowhead Pharmaceuticals, Inc. | 2019-12-19 | — | — | US | disclosed |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-09-26 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885LPAR1 2824/4885 |
| US-10995335-B2 | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use | TEK, PLIN3, PNLIP | GLP1R 459/4885LPAR3 123/4885LPAR1 526/4885 |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885LPAR1 2824/4885 |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885LPAR1 2824/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885LPAR1 2824/4885 |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885LPAR3 205/4885LPAR1 951/4885 |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885LPAR3 205/4885LPAR1 951/4885 |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, EIF2AK2, IFNAR1 | GLP1R 4338/4885LPAR3 1993/4885LPAR1 1943/4885 |
| US-10780108-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | HAVCR2, EIF2AK2, HDGF | GLP1R 4794/4885LPAR3 860/4885LPAR1 1566/4885 |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, EIF2AK2 | GLP1R 4386/4885LPAR3 1483/4885LPAR1 1221/4885 |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | GLP1R 459/4885LPAR3 123/4885LPAR1 526/4885 |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | F12, F13A1, F13B | GLP1R 4018/4885LPAR3 842/4885LPAR1 1117/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.